MONTREAL, Nov. 09, 2021 (GLOBE NEWSWIRE) – C3i Center Inc. has strengthened our position as a Canadian leader in contract development and manufacturing in cell therapy with two significant developments.
First, we are delighted to announce that our laboratories based in Montreal, Canada have received accreditation from the Laboratory Accreditation Program (CAP) of the College of American Pathologists. CAP accreditation is a globally recognized program designed to maintain the highest level of excellence in laboratory practice. During the accreditation process, inspectors review laboratory records and quality control procedures from the previous two years. CAP inspectors also review the qualifications of laboratory personnel, equipment, facilities, safety program and overall management. The US federal government recognizes the CAP as equal to or more stringent than its own inspection program.
“Obtaining CAP accreditation is an important step that reaffirms our long-standing commitment to meet the most rigorous scientifically-based requirements for our customers,” said Louisa Petropoulos, CEO of C3i Center Inc. “This is testament to the integrity of our laboratory standards, which in turn supports our GMP manufacturing of cell and gene therapies and enables us to deliver the highest quality results as we help companies move their technologies through phase testing 1 until commercialization.
C3i is also pleased to announce the creation of C3i Laboratories Inc., a private spin-off company that will focus on advancing Canada’s capacity in biomarker, diagnostic and analytical testing.
“These two developments are a testament to our brilliant and dedicated laboratory teams and their ability to perform at the highest level every day,” said Dr. Lambert Busque, Laboratory Director and Medical Director of Center C3i Inc .. “This provides a of great value to our partners and is of critical importance to patients who benefit from advanced cell and gene therapies. “
About Center C3i inc.
C3i Center Inc. is a leading CDMO providing turnkey services in the development and commercialization of cell and gene therapies, including CRO, immune monitoring services for biomarker development to the pharmaceutical and biotechnology industry. In addition, C3i supports Canadian innovations through cash and in-kind contributions. Founded in 2016, it is based in Montreal, Quebec, with a satellite office in the MaRS Discovery District in Toronto, Ontario. C3i Laboratories inc. is based in Laval, Quebec. http://centrec3i.com